Depletion of microglia, but not T cells, improved neurocognitive function after anti-PD1 treatment, and targeting Syk reduced MHC-II expression on microglia and enhanced neurocognitive activity without affecting the anti-tumor efficacy of anti-PD1 treatment (139). Here, PDCD1 is linked to neoplasm.